Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05588609 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
A Phase 2 study, sponsored by Partner Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT05588609: Clinical Trial Phase 2 study, sponsored by Partner Therapeutics.
NCT05588609 is a Phase 2 study that was terminated before completion, run by Partner Therapeutics. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05588609, a Phase 2 study, was terminated before completion, sponsored by Partner Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC
Primary Outcome
Objective Response Rate (ORR) by local assessment per RECIST v1.1
Interventions
- DRUG Afatinib Oral Tablet
- DRUG Enzalutamide Pill
- DRUG Abiraterone acetate tablets
- BIOLOGICAL MCLA-128
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-11-17 |
| Est. Completion | 2025-07-03 |
| Phase | Phase 2 |
Why NCT05588609 stopped before completion
NCT05588609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 4 interventions - of which Afatinib Oral Tablet is the first listed.
NCT05588609 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05588609 about?
NCT05588609 is a clinical study titled "Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers". This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC
What is the current status of trial NCT05588609?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2022-11-17. Estimated completion is 2025-07-03.
What interventions are being tested in trial NCT05588609?
The interventions under investigation include: Afatinib Oral Tablet (DRUG), Enzalutamide Pill (DRUG), Abiraterone acetate tablets (DRUG), MCLA-128 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05588609?
This trial is sponsored by Partner Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05588609's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI